Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Manzanita Pharmaceuticals Inc
Profile last edited on: 7/6/2018      CAGE: 4PAW0      UEI: J4S6AKLE7EC5

Business Identifier: Glucocorticoid to treat chronic pain
Year Founded
2007
First Award
2013
Latest Award
2018
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2995 Woodside Road Suite 400 Pmb 309
Woodside, CA 94062
   N/A
   N/A
   manzanitapharmaceuticals.com/
Location: Single
Congr. District: 14
County: San Mateo

Public Profile

Manzanita Pharmaceuticals, Inc. was founded with the acquisition of intellectual property assets of Asilomar Pharmaceuticals, Inc. which filed for bankruptcy in June 2006. The company was founded on an idea supported by DARPA. Manzanita Pharmaceuticals's is focused on developing a modified glucocorticoid to treat chronic pain.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$288,301
Phase II Dollars
$1,972,907
Total Awarded
$2,261,208

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2018 2 NIH $2,261,208
Project Title: In Vivo Feasibility of a Peripheral Nerve Imaging Agent

Key People / Management

  Constance Mckee -- President & Ceo

  Robert G Dalziel -- Chair, Scientific Advisory Board

  Stephen B Kahl -- Scientific Advisor

  Robert R Webb -- Chief Scientific Officer

Company News

There are no news available.